TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 16-week Treatment, Multicenter, Randomized, Double Blind, Placebo-controlled, Parallel-group Study to Assess the Effect of Omalizumab on the Expression of FcεRI Receptors of Blood Basophils and Dendritic Cells in Patients With Severe Persistent Non-atopic Asthma, Uncontrolled Despite Optimal Therapy
Brief Summary: This study will assess the change in the expression of FcεRI receptors of blood basophils and dendritic cells after 16 weeks of treatment with omalizumab as compared with placebo, in adult patients with non-atopic severe persistent asthma, uncontrolled despite optimal therapy.


Options:
A: Arm Label: Reslizumab; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Reslizumab; Assigned to Arm(s): Reslizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Mepolizumab SC; Type: EXPERIMENTAL; Interventions: Biological: Mepolizumab, Drug: SOC | Arm Label: Placebo SC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: SOC | Intervention Type: BIOLOGICAL; Name: Mepolizumab; Assigned to Arm(s): Mepolizumab SC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo SC | Intervention Type: DRUG; Name: SOC; Assigned to Arm(s): Mepolizumab SC, Placebo SC
C: Arm Label: Omalizumab; Type: EXPERIMENTAL; Interventions: Drug: omalizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: CNTO 148 (golimumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO148 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CNTO148; Assigned to Arm(s): CNTO 148 (golimumab) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 16-week Treatment, Multicenter, Randomized, Double Blind, Placebo-controlled, Parallel-group Study to Assess the Effect of Omalizumab on the Expression of FcεRI Receptors of Blood Basophils and Dendritic Cells in Patients With Severe Persistent Non-atopic Asthma, Uncontrolled Despite Optimal Therapy
Brief Summary: This study will assess the change in the expression of FcεRI receptors of blood basophils and dendritic cells after 16 weeks of treatment with omalizumab as compared with placebo, in adult patients with non-atopic severe persistent asthma, uncontrolled despite optimal therapy.


Options:
A: Arm Label: Omalizumab; Type: EXPERIMENTAL; Interventions: Drug: omalizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK679586 | Intervention Type: DRUG; Name: GSK679586; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: MEDI528 50 mg; Type: EXPERIMENTAL; Interventions: Biological: MEDI528 50 mg | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Other: PLACEBO | Intervention Type: BIOLOGICAL; Name: MEDI528 50 mg; Assigned to Arm(s): MEDI528 50 mg | Intervention Type: OTHER; Name: PLACEBO; Assigned to Arm(s): PLACEBO
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab (MILR1444A) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: lebrikizumab (MILR1444A); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Specified Work Site Physical Activity Intervention on Musculoskeletal Disorders Among Employees With Physical Heavy Work
Brief Summary: The purpose of this study is to evaluate the effect of specified worksite physical-activity interventions on musculoskeletal disorders in an industry with physical heavy workload.


Options:
A: Arm Label: Reference; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health check only | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity and Health check | Intervention Type: BEHAVIORAL; Name: Physical activity and Health check; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Health check only; Assigned to Arm(s): Reference
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Workplace Solutions Consulting approach | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Delayed intervention | Intervention Type: BEHAVIORAL; Name: Workplace Solutions Consulting approach; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Delayed intervention; Assigned to Arm(s): 2
C: Arm Label: Worksite Environmental Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: weight gain prevention | Arm Label: No-contact control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: weight gain prevention; Assigned to Arm(s): Worksite Environmental Intervention
D: Arm Label: Stair walking; Type: EXPERIMENTAL; Interventions: Behavioral: Stair walking | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Stair walking | Intervention Type: BEHAVIORAL; Name: Stair walking; Assigned to Arm(s): Control, Stair walking

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of topical application of IDP-108 versus vehicle in treating patients with onychomycosis.


Options:
A: Arm Label: Nd:YAG laser pulse therapy; Type: EXPERIMENTAL; Interventions: Device: Nd:YAG laser pulse therapy | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: Sham procedure | Intervention Type: DEVICE; Name: Nd:YAG laser pulse therapy; Assigned to Arm(s): Nd:YAG laser pulse therapy | Intervention Type: DEVICE; Name: Sham procedure; Assigned to Arm(s): Sham
B: Arm Label: Excilor Forte; Type: EXPERIMENTAL; Interventions: Device: Excilor Forte | Arm Label: Loceryl 5%; Type: ACTIVE_COMPARATOR; Interventions: Drug: Loceryl 5% | Intervention Type: DEVICE; Name: Excilor Forte; Assigned to Arm(s): Excilor Forte | Intervention Type: DRUG; Name: Loceryl 5%; Assigned to Arm(s): Loceryl 5%
C: Arm Label: IDP-108; Type: EXPERIMENTAL; Interventions: Drug: IDP-108 | Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle | Intervention Type: DRUG; Name: IDP-108; Assigned to Arm(s): IDP-108 | Intervention Type: DRUG; Name: Vehicle; Assigned to Arm(s): Vehicle
D: Arm Label: IDP-108; Type: EXPERIMENTAL; Interventions: Drug: IDP-108 | Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle | Intervention Type: DRUG; Name: IDP-108; Assigned to Arm(s): IDP-108 | Intervention Type: DRUG; Name: Vehicle; Assigned to Arm(s): Vehicle

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of topical application of IDP-108 versus vehicle in treating patients with onychomycosis.


Options:
A: Arm Label: Excilor Forte; Type: EXPERIMENTAL; Interventions: Device: Excilor Forte | Arm Label: Loceryl 5%; Type: ACTIVE_COMPARATOR; Interventions: Drug: Loceryl 5% | Intervention Type: DEVICE; Name: Excilor Forte; Assigned to Arm(s): Excilor Forte | Intervention Type: DRUG; Name: Loceryl 5%; Assigned to Arm(s): Loceryl 5%
B: Arm Label: Nd:YAG laser pulse therapy; Type: EXPERIMENTAL; Interventions: Device: Nd:YAG laser pulse therapy | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: Sham procedure | Intervention Type: DEVICE; Name: Nd:YAG laser pulse therapy; Assigned to Arm(s): Nd:YAG laser pulse therapy | Intervention Type: DEVICE; Name: Sham procedure; Assigned to Arm(s): Sham
C: Arm Label: IDP-108; Type: EXPERIMENTAL; Interventions: Drug: IDP-108 | Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle | Intervention Type: DRUG; Name: IDP-108; Assigned to Arm(s): IDP-108 | Intervention Type: DRUG; Name: Vehicle; Assigned to Arm(s): Vehicle
D: Arm Label: IDP-108; Type: EXPERIMENTAL; Interventions: Drug: IDP-108 | Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle | Intervention Type: DRUG; Name: IDP-108; Assigned to Arm(s): IDP-108 | Intervention Type: DRUG; Name: Vehicle; Assigned to Arm(s): Vehicle

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Is Antibiotic Therapy Mandatory for Treatment of Uncomplicated Acute Colonic Diverticulitis: a Randomized Clinical Trial
Brief Summary: The purpose of this study is to evaluate if antibiotic therapy is necessary for treatment of uncomplicated colonic diverticulitis.

The hypothesis is that Patients with acute uncomplicated colonic diverticulitis will recover the condition without antibiotic therapy and the lack of antibiotic therapy will not lead to complications.

The patients will be randomized to conservative treatment with and without antibiotic therapy.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Dietary Advice, Drug: Antibiotic for Diverticulitis | Arm Label: Mesalamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalamine, Other: Dietary Advice, Drug: Antibiotic for Diverticulitis | Arm Label: Mesalamine & Probiotic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Probiotic, Other: Dietary Advice, Drug: Antibiotic for Diverticulitis | Intervention Type: DRUG; Name: Mesalamine; Assigned to Arm(s): Mesalamine | Intervention Type: DRUG; Name: Probiotic; Assigned to Arm(s): Mesalamine & Probiotic | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: OTHER; Name: Dietary Advice; Assigned to Arm(s): Mesalamine, Mesalamine & Probiotic, Placebo | Intervention Type: DRUG; Name: Antibiotic for Diverticulitis; Assigned to Arm(s): Mesalamine, Mesalamine & Probiotic, Placebo
B: Arm Label: Mesalazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine 800 mg | Arm Label: Lactobacillus casei; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lactobacillus casei | Arm Label: Mesalazine plus Lactobacillus casei; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine plus Lactobacillus casei | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Mesalazine placebo plus Lactobacillus casei placebo | Intervention Type: DRUG; Name: Mesalazine plus Lactobacillus casei; Assigned to Arm(s): Mesalazine plus Lactobacillus casei | Intervention Type: DRUG; Name: Mesalazine placebo plus Lactobacillus casei placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Mesalazine 800 mg; Assigned to Arm(s): Mesalazine | Intervention Type: DRUG; Name: Lactobacillus casei; Assigned to Arm(s): Lactobacillus casei
C: Arm Label: mesalamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: mesalamine | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: mesalamine; Assigned to Arm(s): mesalamine | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Antibiotic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antibiotic | Arm Label: No antibiotic; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Antibiotic; Assigned to Arm(s): Antibiotic

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Is Antibiotic Therapy Mandatory for Treatment of Uncomplicated Acute Colonic Diverticulitis: a Randomized Clinical Trial
Brief Summary: The purpose of this study is to evaluate if antibiotic therapy is necessary for treatment of uncomplicated colonic diverticulitis.

The hypothesis is that Patients with acute uncomplicated colonic diverticulitis will recover the condition without antibiotic therapy and the lack of antibiotic therapy will not lead to complications.

The patients will be randomized to conservative treatment with and without antibiotic therapy.


Options:
A: Arm Label: Antibiotic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antibiotic | Arm Label: No antibiotic; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Antibiotic; Assigned to Arm(s): Antibiotic
B: Arm Label: Cephalosporin + Metronidazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cephalosporin + Metronidazole | Arm Label: No antibiotic; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Cephalosporin + Metronidazole; Assigned to Arm(s): Cephalosporin + Metronidazole
C: Arm Label: Symptomatic treatment with NSAID; Type: EXPERIMENTAL; Interventions: Drug: Ibuprofen, Drug: Acetaminophen | Arm Label: Antibiotic+symptomatic treatment with NSAID; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ibuprofen, Drug: Acetaminophen, Drug: Amoxicillin/clavulanic acid | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Antibiotic+symptomatic treatment with NSAID, Symptomatic treatment with NSAID | Intervention Type: DRUG; Name: Acetaminophen; Assigned to Arm(s): Antibiotic+symptomatic treatment with NSAID, Symptomatic treatment with NSAID | Intervention Type: DRUG; Name: Amoxicillin/clavulanic acid; Assigned to Arm(s): Antibiotic+symptomatic treatment with NSAID
D: Arm Label: Conservative strategy with antibiotics; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amoxicillin-clavulanate | Arm Label: Liberal strategy without antibiotics; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Amoxicillin-clavulanate; Assigned to Arm(s): Conservative strategy with antibiotics

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Dynamics of Human Atrial Fibrillation
Brief Summary: The study is conducted in patients with atrial fibrillation undergoing clinically prescribed ablation. The study hypothesis is that ablation at specific sites that are identified to 'drive' the atrial fibrillation may improve the success of the ablation procedure.


Options:
A: Arm Label: Rhythm Control; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Rhythm control | Arm Label: Rate Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Rate Control | Intervention Type: PROCEDURE; Name: Rhythm control; Assigned to Arm(s): Rhythm Control | Intervention Type: OTHER; Name: Rate Control; Assigned to Arm(s): Rate Control
B: N/A
C: Intervention Type: PROCEDURE; Name: Circumferential Pulmonary Vein Ablation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Antiarrhythmic Drug Therapy; Assigned to Arm(s): N/A
D: Arm Label: medical therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: ACE inhibitor - ramipril, enalapril, captopril, perindopril, lisinopril, Drug: Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol, Drug: Aldosterone Antagonists - spironolactone | Arm Label: Radiofrequency ablation (RFA); Type: ACTIVE_COMPARATOR; Interventions: Procedure: radiofrequency ablation | Intervention Type: PROCEDURE; Name: radiofrequency ablation; Assigned to Arm(s): Radiofrequency ablation (RFA) | Intervention Type: DRUG; Name: ACE inhibitor - ramipril, enalapril, captopril, perindopril, lisinopril; Assigned to Arm(s): medical therapy | Intervention Type: DRUG; Name: Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol; Assigned to Arm(s): medical therapy | Intervention Type: DRUG; Name: Aldosterone Antagonists - spironolactone; Assigned to Arm(s): medical therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Analgesic Effectiveness of Potassium Diclofenac for Retinal Photocoagulation in Patients With High-risk Proliferative Diabetic Retinopathy
Brief Summary: The purpose of this study was to evaluate the analgesic effect of oral potassium diclofenac in patients with proliferative diabetic retinopathy submitted to retinal photocoagulation.

Two groups of patients were followed and the effect of the treatment (diclofenac plus laser) was compared to placebo (placebo plus laser). Pain associated with treatment was recorded using a Visual Analog Scale 15 minutes after the procedure.


Options:
A: Arm Label: Ranibizumab 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Sham injection/ranibizumab 0.5 mg; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab 0.3 mg, Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection/ranibizumab 0.5 mg
B: Arm Label: 7 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Arm Label: 20 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Arm Label: sham; Type: SHAM_COMPARATOR; Interventions: Other: sham | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 20 days, 7 days | Intervention Type: OTHER; Name: sham; Assigned to Arm(s): sham
C: Arm Label: Placebo first (scheme 2); Type: OTHER; Interventions: Drug: potassium diclofenac | Arm Label: Diclofenac first (scheme 1); Type: OTHER; Interventions: Drug: potassium diclofenac | Intervention Type: DRUG; Name: potassium diclofenac; Assigned to Arm(s): Diclofenac first (scheme 1), Placebo first (scheme 2)
D: Arm Label: Ranibizumab 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Sham injection/ranibizumab 0.5 mg; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab 0.3 mg, Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection/ranibizumab 0.5 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Analgesic Effectiveness of Potassium Diclofenac for Retinal Photocoagulation in Patients With High-risk Proliferative Diabetic Retinopathy
Brief Summary: The purpose of this study was to evaluate the analgesic effect of oral potassium diclofenac in patients with proliferative diabetic retinopathy submitted to retinal photocoagulation.

Two groups of patients were followed and the effect of the treatment (diclofenac plus laser) was compared to placebo (placebo plus laser). Pain associated with treatment was recorded using a Visual Analog Scale 15 minutes after the procedure.


Options:
A: Arm Label: Panretinal photocoagulation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Panretinal photocoagulation | Arm Label: Bevacizumab + Panretinal Photocoagulation (PRP); Type: EXPERIMENTAL; Interventions: Procedure: Procedure: Panretinal Photocoagulation (PRP) Drug: Intravitreous injection of Bevacizumab | Intervention Type: PROCEDURE; Name: Panretinal photocoagulation; Assigned to Arm(s): Panretinal photocoagulation | Intervention Type: PROCEDURE; Name: Procedure: Panretinal Photocoagulation (PRP) Drug: Intravitreous injection of Bevacizumab; Assigned to Arm(s): Bevacizumab + Panretinal Photocoagulation (PRP)
B: Arm Label: Avastin Injection Group (AIG); Type: EXPERIMENTAL; Interventions: Drug: Avastin (bevacizumab) | Arm Label: Sham Injection Group (SIG); Type: SHAM_COMPARATOR; Interventions: Other: Sham injection | Intervention Type: DRUG; Name: Avastin (bevacizumab); Assigned to Arm(s): Avastin Injection Group (AIG) | Intervention Type: OTHER; Name: Sham injection; Assigned to Arm(s): Sham Injection Group (SIG)
C: Arm Label: Placebo first (scheme 2); Type: OTHER; Interventions: Drug: potassium diclofenac | Arm Label: Diclofenac first (scheme 1); Type: OTHER; Interventions: Drug: potassium diclofenac | Intervention Type: DRUG; Name: potassium diclofenac; Assigned to Arm(s): Diclofenac first (scheme 1), Placebo first (scheme 2)
D: Arm Label: Intravitreal anti-VEGF; Type: EXPERIMENTAL; Interventions: Drug: Intravitreal injection of ranibizumab | Intervention Type: DRUG; Name: Intravitreal injection of ranibizumab; Assigned to Arm(s): Intravitreal anti-VEGF

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Development and Evaluation of a Diabetes-specific Cognitive Behavioural Treatment (DS-CBT) for Diabetic Patients With Subthreshold Depression
Brief Summary: This work is supported by the "Kompetenznetz Diabetes mellitus (Competence Network for Diabetes mellitus)" funded by the Federal Ministry of Education and Research (FKZ 01GI0809).

Approximately one third of diabetic patients has elevated depressive symptoms. The majority of these patients are suffering from a subthreshold depression. In spite of the fact that subthreshold depression has an equivalent negative impact on the prognosis of diabetes as clinical depression, there is no specific intervention tool. The main objective of this project is to develop a diabetes specific cognitive behavioural treatment (DS-CBT) for diabetic patients with subthreshold depression. In a randomized trail DS-CBT is compared to standard diabetes education. A total of 188 diabetic patients will be recruited and randomly assigned to the two treatment conditions. The expected main outcome is the reduction of subthreshold depression under DS-CBT in a 12 month follow up. Secondary variables are improvement of glycaemic control, quality of life, diabetes self-management as well as reduction of health care costs and modification of inflammatory parameters.


Options:
A: Intervention Type: BEHAVIORAL; Name: Self-management of chronic illness; Assigned to Arm(s): N/A
B: Arm Label: Home Telemonitoring; Type: EXPERIMENTAL; Interventions: Device: Intel Health Guide | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: DEVICE; Name: Intel Health Guide; Assigned to Arm(s): Home Telemonitoring | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Arm Label: Conventional care, controlgroup; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: integrated health care chain; Type: EXPERIMENTAL; Interventions: Other: integrated health care chain | Intervention Type: OTHER; Name: integrated health care chain; Assigned to Arm(s): integrated health care chain
D: Arm Label: Diabetes-Specific CBT (DS-CBT); Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes-Specific CBT (DS-CBT) | Arm Label: Standard Diabetes Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Diabetes Education | Intervention Type: BEHAVIORAL; Name: Diabetes-Specific CBT (DS-CBT); Assigned to Arm(s): Diabetes-Specific CBT (DS-CBT) | Intervention Type: BEHAVIORAL; Name: Standard Diabetes Education; Assigned to Arm(s): Standard Diabetes Education

Answer: D